InsidersTradesSigma
Follow the 健帆生物 share price and the full insider trade history of the company, a listed issuer based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 健帆生物 has logged 6 insider filings. Market capitalisation: €14.7bn. The latest transaction was disclosed on 13 January 2023 (Sale). Among the most active insiders: 何小莲. The full history is accessible without an account.
6
Insider Decl.
n/a
Thresholds
€13m
2 ops.
Buy Volume
€911,927
4 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,762 of 29,063 companies
63.1
score / 100
Value47
Quality79
FCF yld3.7%
Earn yld3.6%
EV/EBITDA19.1x
ROE16%
Gross mgn79%
Net mgn26%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 January 2023
Declarations6 total
6 of 6 declarations
关于 健帆生物
健帆生物是一家专注于健康和制药领域的公司，专门从事生物解决方案的开发。该公司在XSHE市场上市。